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Abstract  
 
Background 
Trabecular metal (TM) coated acetabular components are increasingly used in both primary 
and revision total hip arthroplasty (THA). However, previous studies assessing TM 
acetabular components have been small single-centre cohorts with most lacking a control 
group. We compared revision rates following primary THA between TM and non-TM coated 
acetabular components. 
 
Methods 
A retrospective observational study was performed using National Joint Registry data, which 
included primary THAs with the same cementless acetabular component (either TM or non-
TM coated). TM and non-TM implants were matched for multiple potential confounding 
factors using propensity scores. Outcomes following primary THA (revision for all-cause 
acetabular indications, aseptic acetabular loosening, and infection) were compared between 
matched groups using competing risk regression analysis. 
 
Results 
In 18,200 primary THAs (9,100 TM and 9,100 non-TM), the overall prevalence of acetabular 
revision, revision for aseptic acetabular loosening, and septic revision was 1.2%, 0.13%, and 
0.59% respectively. Five-year revision rates for all-causes (1.0% vs. 1.8%; sub-hazard ratio 
*Abstract (Structured; 250 Words Maximum)
 (SHR)=0.57, 95% CI=0.43-0.76; p<0.001), aseptic acetabular loosening (0.1% vs. 0.2%; 
SHR=0.35, CI=0.14-0.90; p=0.029), and infection (0.5% vs. 0.9%; SHR=0.51, CI=0.34-0.76; 
p=0.001) were all lower in TM compared with non-TM implants. 
 
Conclusion 
Following primary THA, TM coated implants had a reduced risk of both aseptic and septic 
revision compared with non-TM implants. Although absolute differences in revision risk 
were small, they may be clinically significant if TM designs were implanted in more complex 
cases. 
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Introduction 51 
Revision surgery for failed total hip arthroplasties (THAs) remains a significant problem, 52 
especially in young patients with high activity levels [1-3]. Aseptic component loosening 53 
represents the leading reason for THA failure, whilst periprosthetic joint infection is a 54 
common cause of early revision that presents a challenging problem to surgeons [4-6]. 55 
 56 
Over the years, THA implants have been modified with the aim to reduce subsequent failures. 57 
Trabecular metal
TM
 (TM; Zimmer-Biomet; Warsaw, Indiana, USA) is a material made from 58 
elemental tantalum, which is highly porous with a high coefficient of friction and a modulus 59 
of elasticity similar to cancellous bone, with studies observing that TM has a higher potential 60 
for osteointegration, which may reduce subsequent implant failures [7-9]. These attractive 61 
properties have led to increased usage of TM coated acetabular components in both primary 62 
and revision THA [4, 8, 10, 11]. In primary THA, TM implants have demonstrated good 63 
fixation at medium-term follow-up on radiostereometric analysis,[11-13] with one small 64 
cohort suggesting good clinical outcomes can be achieved at 15-years follow-up [14]. 65 
Following revision THA, lower failure rates have been observed when using TM implants 66 
compared with non-TM designs,[10, 15, 16] with recent evidence suggesting that TM may 67 
reduce the risk of re-infection following septic revisions [10]. 68 
 69 
However studies assessing TM acetabular components to date have been limited by being 70 
small single-centre cohorts, with many lacking a comparator group [8, 10-16]. Given the risk 71 
of failure is generally low, especially after primary THA, it is important to assess the clinical 72 
efficacy of TM acetabular components in large cohorts that are appropriately powered to 73 
detect differences in revision rates between TM and non-TM implants. Furthermore whilst 74 
there may be potential clinical benefits of TM implants it is important to also consider the 75 
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financial implications, as these can be up to 30% more expensive than non-TM components. 76 
Therefore, TM acetabular components must demonstrate significantly lower failure rates 77 
compared with non-TM components to support their continued use. 78 
 79 
The National Joint Registry (NJR) for England and Wales was established in April 2003 to 80 
identify poorly performing implants early [4]. It is the largest arthroplasty registry in the 81 
world, and contains details of two million joint replacement procedures. We used NJR data to 82 
compare revision rates following primary THA between TM and non-TM coated acetabular 83 
components. 84 
 85 
 86 
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Patients and Methods 101 
A retrospective observational study was performed using NJR data. The NJR records all hip 102 
arthroplasty procedures performed at all hospitals in England and Wales since 2003, with 103 
93% of patients consenting for their details to be recorded within the NJR [4]. The NJR 104 
collects data on patient factors (including age, gender, American Society of Anesthesiologists 105 
(ASA) grade) and surgical factors (including surgical approach, indication, and components 106 
implanted) for each arthroplasty procedure, which is obtained using data capture forms 107 
completed by the operating surgeon. Unique patient identifiers allow primary THAs to be 108 
linked to any subsequent surgical procedures in which components are removed or 109 
exchanged, with 94.5% linkability currently reported [4]. Before obtaining the dataset, the 110 
NJR database was linked using unique patient identifiers with the Office for National 111 
Statistics, which provides data on all-cause mortality. 112 
 113 
Anonymised patient data were extracted from the NJR, which included all primary THAs 114 
recorded between 1st April 2003 and 30
th
 July 2015 in which one of four cementless 115 
acetabular component designs were implanted (n=53,963). The latter study date allowed a 116 
minimum 1-year follow-up period for determining outcomes after primary THA. The four 117 
acetabular component designs studied were all produced by one manufacturer (Zimmer-118 
Biomet), and either had a TM (TM Modular and Continuum) or non-TM (Trilogy and 119 
Trilogy IT) surface coating. For the purposes of this study these acetabular component 120 
designs could be implanted with any bearing surface and femoral component, regardless of 121 
manufacturer. Hips were subsequently excluded if any data regarding the primary THA 122 
procedure performed (stem fixation, femoral head size, bearing surface) were either missing 123 
or ambiguous (n=1,997). There were 51,966 primary THAs (12,056 TM and 39,910 non-TM) 124 
eligible for study inclusion (Table 1). 125 
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 126 
The Trilogy acetabular component was released in 1993, and has a fully hemispherical design 127 
with a pure titanium fiber metal coating. The component is available in 2 mm increments 128 
(ranging from 40 mm to 70 mm outer diameter depending on the specific shell design), and 129 
has a locking ring mechanism for securing polyethylene liners. The TM Modular acetabular 130 
component was released in 2003, and has identical internal geometry to the Trilogy, with the 131 
only difference between the two designs being the surface coating. The Trilogy IT acetabular 132 
component was released in 2009, and is similar in design to the Trilogy, but internally 133 
possess both an integrated taper and a locking groove which can accommodate polyethylene 134 
and ceramic liners. The Continuum acetabular component was introduced in 2009, and has 135 
identical internal geometry to the Trilogy IT, with the only difference between the two 136 
designs being the surface coating. All four acetabular components can be implanted in 137 
primary and revision THA. 138 
 139 
The binary study exposure of interest was whether the primary THA included a TM coated or 140 
a non-TM coated acetabular component. These two groups were matched for multiple 141 
potential confounding factors using propensity scores (detailed below). By controlling for 142 
patient and surgical covariates, the use of propensity score matching would allow the true 143 
effect of implant coating on the risk of revision surgery to be more accurately assessed. This 144 
a priori decision was supported by the substantial differences in the patient and surgical 145 
characteristics that were observed between the unmatched TM and non-TM groups (Table 1); 146 
these differences could not have been adequately controlled for using adjusted multivariable 147 
regression models. 148 
 149 
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Study outcomes of interest following primary THA were: (1) acetabular component revision 150 
for all-causes (with or without femoral component revision), (2) acetabular component 151 
revision for aseptic loosening (with or without femoral component revision), and (3) revision 152 
for infection (regardless of whether or not the acetabular component was revised). 153 
 154 
Statistical analysis 155 
All analyses were performed using Stata (Version 14.2; Lakeway Drive, Texas, USA) apart 156 
from propensity score matching, which was performed using R (Version 3.4.0; R Foundation 157 
for Statistical Computing, Vienna, Austria). The significance level for all analyses was a p-158 
value <0.05, with 95% confidence intervals (CI) also used. 159 
 160 
Primary THAs with TM and non-TM implants were matched for multiple potential patient 161 
and surgical confounding factors using propensity score techniques [17, 18]. Matching was 162 
performed using a one-to-one ratio. The algorithm used matched on the logit of the 163 
propensity score with a 0.02 standard deviation caliper width. Greedy matching (each TM hip 164 
was matched to the nearest non-TM hip) without replacement was used (once a match was 165 
made that specific hip was no longer available for matching subsequent cases), which has 166 
demonstrated superior performance for estimating treatment effects [17].  167 
 168 
The TM and non-TM groups were matched for the following covariates where complete data 169 
was available for the entire cohort: age, gender, bilateral THAs, primary hip diagnosis, ASA 170 
grade, year of primary THA, venous thromboembolism prophylaxis, surgeon grade, surgical 171 
approach, and components implanted at primary THA (stem fixation, femoral head size, 172 
bearing surface, and the use of bone graft). Due to the high proportion of missing data (41%), 173 
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the groups were not matched based on body mass index (BMI). Logistic regression was used 174 
to generate a propensity score, representing the probability that a TM implant was used at 175 
primary THA. The TM and non-TM groups were matched based on the individual propensity 176 
scores. Standardised mean differences (SMDs) were examined both before and after 177 
matching to assess for any covariate imbalance between the TM and non-TM groups. 178 
 179 
Cumulative implant survival rates following primary THA for the three study outcomes were 180 
determined using the Kaplan-Meier method. Patients who were alive with a non-revised 181 
primary THA were censored on the study end date (30
th
 July 2016). For the purposes of 182 
implant survival analysis aseptic revision procedures other than the defined outcomes of 183 
interest, such as isolated femoral component revisions or femoral head/acetabular liner only 184 
exchanges, were censored on the date of revision surgery. Outcomes following primary THA 185 
were compared between the matched TM and non-TM groups using Fine and Gray regression 186 
modelling, which accounted for the competing risk of death. The proportional sub-hazards 187 
assumption was assessed and satisfied for all analyses. To account for clustering within the 188 
matched cohort a robust variance estimator was used in the regression models [19]. 189 
Univariable regression models were assessed in the matched cohort as well as adjusted 190 
models. These adjusted models accounted for any residual covariate imbalance following 191 
matching, defined as an SMD of 10% or more for any covariate following matching [20]. As 192 
a sensitivity analysis (not presented) regression was repeated using Cox models, which 193 
produced very similar results to the Fine and Gray models. 194 
 195 
 196 
 197 
 198 
 9 
Results 199 
The matched cohort of 18,200 primary THAs included 9,100 TM hips (3,490 TM Modular 200 
and 5,610 Continuum) and 9,100 non-TM hips (6,144 Trilogy and 2,956 Trilogy IT) (Table 201 
1). Most covariates with imbalance between the TM and non-TM groups before matching 202 
were appropriately balanced after matching. Four covariates had residual imbalance 203 
following matching (age, year of primary THA, ASA grade, and chemical venous 204 
thromboembolism prophylaxis), which were adjusted for in the regression analyses. 205 
 206 
All-cause revision surgery of any component was performed in 594 hips (3.3%) at a mean 207 
time of 1.6 years (range 1 day to 10.0 years) from primary THA. There were 3,412 (18.8%) 208 
deaths occurring at a mean time of 3.6 years (range 1 day to 12.8 years) following primary 209 
THA. The mean follow-up time for the remaining 14,194 (78.0%) unrevised hips was 3.7 210 
years (range 1.0-12.6 years). 211 
 212 
Acetabular component revision for all causes 213 
The overall prevalence of all-cause acetabular component revision was 1.2% (n=211), with 214 
these failures occurring at a mean time of 1.3 years (1 day to 8.6 years) after primary THA. 215 
The commonest indications for acetabular component revision were dislocation/subluxation 216 
(n=100; 47.4% of all acetabular component revisions), infection (n=32; 15.2%), 217 
malalignment (n=29; 13.7%), and aseptic loosening (n=23; 10.9%). All-cause acetabular 218 
component revision rates were significantly lower in primary THAs with TM implants 219 
compared with non-TM implants (Table 2). The 5-year cumulative acetabular component 220 
survival rate following primary THA was 99.0% (CI=98.7%-99.2%) in the TM group 221 
compared with 98.2% (CI=97.8%-98.5%) in the non-TM group (SHR=0.57, CI=0.43-0.76; 222 
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p<0.001) (Figure 1). A regression model adjusting for the four covariates with residual 223 
imbalance following matching produced similar results to the unadjusted models (Table 2). 224 
 225 
Acetabular component revision for aseptic loosening 226 
The overall prevalence of acetabular component revision for aseptic loosening was 0.13% 227 
(n=23), with these occurring at a mean time of 1.2 years (0.02-3.6 years) following primary 228 
THA. Revision rates for aseptic acetabular loosening were significantly lower in primary 229 
THAs with TM implants compared with non-TM implants (Table 2). The 5-year cumulative 230 
implant survival rate free from aseptic acetabular loosening was 99.9% (CI=99.8%-99.9%) in 231 
the TM group compared with 99.8% (CI=99.6%-99.9%) in the non-TM group (SHR=0.35, 232 
CI=0.14-0.90; p=0.029). 233 
 234 
Revision for infection 235 
The overall prevalence of revision for infection was 0.59% (n=108), with revisions 236 
performed at a mean time of 1.3 years (0.04-10.0 years) following primary THA. Revision 237 
rates for infection were significantly lower in primary THAs with TM implants compared 238 
with non-TM implants (Table 2). The 5-year cumulative implant survival rate free from 239 
infection after primary THA was 99.5% (CI=99.3%-99.7%) in the TM group compared with 240 
99.1% (CI=98.8%-99.3%) in the non-TM group (SHR=0.51, CI=0.34-0.76; p=0.001). 241 
 242 
 243 
 244 
 245 
 246 
 247 
 11 
Discussion 248 
The use of TM coated acetabular components in primary and revision THA has been 249 
increasing given that a number of studies have reported good outcomes with these implants, 250 
with some suggesting TM implants have lower failure rates compared with non-TM implants 251 
[4, 10]. However large cohort studies demonstrating any clinical benefits of TM compared 252 
with non-TM implants in primary THA patients are lacking. We used NJR data to compare 253 
revision rates following primary THA between TM and non-TM coated acetabular 254 
components. The present study observed that in matched patients undergoing primary THA, 255 
TM coated implants had a reduced risk of both aseptic and septic revision compared with 256 
non-TM implants. 257 
 258 
Revision rates following primary THA with conventional bearing surfaces are low,[4, 5] 259 
therefore large cohort studies are required to compare implant failures between different 260 
primary THA designs. We observed that both TM and non-TM coated acetabular components 261 
were associated with low revision rates at 5 years following primary THA. The 5-year 262 
acetabular component survival rates for primary TM (99.0%) and non-TM (98.2%) implants 263 
observed in this study both meet the top rating (A* which is equivalent to a revision rate of 264 
less than 0.5% per year) from the Orthopaedic Data Evaluation Panel (ODEP) [21]. Indeed 265 
all four acetabular component designs studied have already achieved the top ODEP rating 266 
[21]. 267 
 268 
In this study however, revision rates for all-causes, aseptic acetabular loosening, and 269 
infection were all significantly lower in primary THAs with TM coatings compared with non-270 
TM coatings. The absolute differences in revision rates for all endpoints between primary 271 
TM and non-TM implants were relatively small, and could initially be deemed not to be of 272 
 12 
clinical significance, especially given that TM implants are more expensive. However in light 273 
of the perceived advantages, many surgeons have used TM coated implants in the most 274 
complex procedures [8, 10, 15]. Therefore the observed differences in revision rates between 275 
primary TM and non-TM implants may be clinically significant if the TM cases studied were 276 
largely implanted in complex cases. Despite matching the TM and non-TM groups for some 277 
factors that may relate to primary THA complexity (such as age, gender, primary hip 278 
diagnosis, and the requirement for bone grafting),[22, 23] it is suspected that this complexity 279 
was not adequately controlled for in this registry dataset. Therefore further studies comparing 280 
primary TM and non-TM coated implants are not only required at extended follow-up to 281 
establish whether the observed differences in implant survival persist, but also to establish if 282 
the use of TM is clinically efficacious compared with non-TM components when used to 283 
treat patients with similar pathology. Such studies also need to be coupled with cost-284 
effectiveness evaluations regarding the use of TM in primary THA. 285 
 286 
Reduced failure rates in TM implants compared with non-TM implants have been reported 287 
previously in studies where these components have been used at revision THA [10, 15]. We 288 
believe this represents the first large cohort to demonstrate similar findings specifically in 289 
primary THA patients. It is suspected that the reduced failure rates in TM implants are a 290 
clinical manifestation of the attractive properties of the TM coating; namely the high porosity, 291 
high coefficient of friction, possession of a similar modulus of elasticity to cancellous bone, 292 
and having an increased potential for osteointegration compared with non-TM implants [7-9]. 293 
Studies have observed superior mechanical stability of TM acetabular components compared 294 
with non-TM components,[24] with good fixation of TM implants confirmed on 295 
radiostereometric analysis at medium-term follow-up after primary THA [11-13]. However 296 
given that aseptic component loosening predominantly occurs at long-term follow-up it is 297 
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important to continue to monitor the performance of TM implants into the second decade 298 
after surgery. Small studies have suggested that TM acetabular components can achieve good 299 
outcomes at 15 years following primary THA,[14] and at 10 years following revision THA 300 
[16]. 301 
 302 
A recent study observed that in THAs revised for infection, the use of TM implants was 303 
associated with a reduced risk of subsequent septic failure compared with non-TM implants 304 
[10]. In primary THAs, we similarly observed decreased revision rates for infection with TM 305 
implants compared to non-TM implants. Possible explanations for the reduced risk of 306 
infection associated with TM coated implants include the increased potential for 307 
osteointegration which subsequently reduces the dead space for colonising organisms, and 308 
the TM surface being more hostile to organisms possibly due to its three-dimensional 309 
structure or other unidentified property [7, 10]. Further research is required to investigate the 310 
potential antibacterial properties of TM coated implants to infecting organisms given that 311 
periprosthetic joint infection continues to pose a devastating problem to arthroplasty patients 312 
with limited advances made in its treatment over the last decade [6]. 313 
 314 
Strengths and limitations 315 
Study strengths include using linked data from the world’s largest arthroplasty registry, 316 
which ensures adequate statistical power. Furthermore assessing an unselected population 317 
reduces the likelihood of sampling bias. Therefore it is suspected that the findings have good 318 
external validity and generalisability, though this requires formal validation. Only acetabular 319 
components with identical designs apart from the TM surface coating were studied to reduce 320 
the risk of confounding related to any other design features. Furthermore robust statistical 321 
methods were used, which included having a large propensity matched comparator group, 322 
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which reduces the risk of the findings being influenced by other potential patient and surgical 323 
confounding factors. Finally, recent studies validating NJR data reported that when 324 
procedures were captured within the NJR the data completion and accuracy were excellent 325 
[25, 26]. 326 
 327 
This study has recognised limitations. Using observational data means causality cannot be 328 
inferred. Although a randomised controlled trial would be the ideal study design to assess 329 
revision rates between two different implants, these are unlikely to be feasible given the large 330 
patient numbers required for adequate statistical power. Revision rates following primary 331 
THA in registries can be underestimated,[25, 26] therefore the observed implant survival 332 
rates represent a best-case scenario. However we suspect that this potential underreporting 333 
would not differ between the TM and non-TM groups. The NJR does not collect 334 
histopathological and microbiological data, therefore revision rates reported for specific 335 
aseptic and septic endpoints presented may differ from the true rates. Registries do not collect 336 
radiological data to assess component migration, although this has been studied extensively 337 
[11-13]. Registries do not collect data on non-revision procedures, such as those performed 338 
for dislocations (closed reductions), infections (debridement and washout), and periprosthetic 339 
fractures (internal fixation), which represents an important outcome measure. 340 
 341 
Despite matching the TM and non-TM groups there is potential for residual confounding. 342 
This is most relevant when considering case complexity. Although this variable was not 343 
adequately accounted for within the NJR, the findings supported lower revision rates in 344 
patients receiving primary TM cups despite these designs being more frequently used in 345 
complex procedures [8, 10, 15]. Nevertheless further studies are needed to assess the clinical 346 
efficacy of TM implants compared with non-TM implants in primary THA patients with 347 
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similar degrees of case complexity, with our data being useful to power such studies. 348 
Matching may also have reduced the generalisibility of our findings given that only 35% of 349 
the unmatched cohort was included in the matched analysis. However the significant baseline 350 
difference between the TM and non-TM groups (Table 1) could not have been adequately 351 
addressed using multivariable regression analysis, therefore supporting the matched approach. 352 
Missing BMI data could have potentially affected our analysis, however BMI was 353 
appropriately balanced between the TM and non-TM groups after matching (Table 1: SMD 354 
of less than 10%). The NJR does not collect data on important factors such as patient 355 
smoking status, comorbidities (including diabetes, rheumatoid arthritis, and other conditions 356 
causing immunosuppression) and medication use (steroids and immunosuppression drugs). 357 
The present study is limited by not being able to match the TM and non-TM groups for these 358 
factors given that they may influence revision rates, specifically revisions performed for 359 
infection. It is recommended that future studies match for these important factors, for 360 
example by using the Charlson Comorbidity Index. Finally, the findings cannot be assumed 361 
to apply to similar highly porous acetabular component designs produced by other 362 
manufacturers. 363 
 364 
Conclusions 365 
This large nationwide study observed that both TM and non-TM coated acetabular 366 
components were associated with low revision rates at 5 years following primary THA. 367 
However, in matched patients undergoing primary THA, TM coated implants had a reduced 368 
risk of both aseptic and septic revision compared with non-TM implants. Although the 369 
differences in revision risk between the groups were small, they may be clinically significant 370 
if the TM designs were implanted in the most complex cases. Future studies should assess 371 
whether the observed differences in revision rates persist at extended follow-up. Furthermore 372 
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it must be determined whether the use of TM coated acetabular components in primary THA 373 
is clinically efficacious given their increased cost. 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
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Figure 1
Click here to download high resolution image
 Figure Legends 
 
Figure 1 Cumulative acetabular component survival rate following primary total hip 
arthroplasty at up to five-years in trabecular metal and non-trabecular metal coated implants 
 
CI = confidence interval; TM = trabecular metal 
Shaded area represents the respective upper and lower limits of the 95% confidence interval 
Figure Legend Page
Table 1 Patient and surgical factors before and after propensity score matching 
 
 
 
Unmatched cohort Matched cohort 
All primary 
THAs 
(n=51,966) 
(100%) 
Non-TM 
cups 
(n=39,910) 
(76.8%) 
TM cups 
 
(n=12,056) 
(23.2%) 
SMD All primary 
THAs 
(n=18,200) 
(100%) 
Non-TM 
cups 
(n=9,100) 
(50%) 
TM cups 
 
(n=9,100) 
(50%) 
SMD 
Covariate         
Gender 
Female vs. male 
 
32,127 
(61.8)  
 
24,954 
(62.5) 
 
7,173  
(59.5) 
 
0.062 
 
11,291 
(62.0) 
 
5,625  
(61.8) 
 
5,666  
(62.3) 
 
0.009 
Age at primary (yr) 
Mean (SD) 
 
68.4 (11.1) 
 
69.5 (10.1) 
 
64.8 (13.2) 
 
0.394 
 
68.0 (12.4) 
 
68.8 (12.1) 
 
67.2 (12.6) 
 
0.130 
BMI (kg/m
2
) * 
Mean (SD) 
 
28.5 (5.3) 
 
28.3 (5.2) 
 
29.1 (5.7) 
 
0.133 
 
28.7 (5.5) 
 
28.6 (5.3) 
 
28.9 (5.7) 
 
0.055 
Bilateral hips 9,677 (18.6)  7,499 (18.8) 2,178 (18.1) 0.019 2,919 (16.0) 1,353 (14.9) 1,566 (17.2) 0.064 
Primary diagnosis 
Primary OA vs. other 
 
47,820 
(92.0) 
 
37,347 
(93.6) 
 
10,473 
(86.9) 
 
0.227 
 
15,897 
(87.4) 
 
7,864  
(86.4) 
 
8,033  
(88.3) 
 
0.056 
Primary year 
2002 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
2013 
2014 
2015 
 
2 (0.004) 
625 (1.2) 
1,494 (2.9) 
2,120 (4.1) 
2,950 (5.7) 
3,434 (6.6) 
3,747 (7.2) 
3,849 (7.4) 
4,120 (7.9) 
5,469 (10.5) 
5,964 (11.5) 
6,222 (12.0) 
7,416 (14.3) 
4,554  (8.8) 
 
2 (0.01) 
624 (1.6) 
1,490 (3.7) 
2,070 (5.2) 
2,814 (7.1) 
3,146 (7.9) 
3,426 (8.6) 
3,432 (8.6) 
2,881 (7.2) 
3,562 (8.9) 
3,875 (9.7) 
4,266 (10.7) 
5,071 (12.7) 
3,251 (8.2) 
 
0 (0.0) 
1 (0.01) 
4 (0.03) 
50 (0.4) 
136 (1.1) 
288 (2.4) 
321 (2.7) 
417 (3.5) 
1,239 (10.3) 
1,907 (15.8) 
2,089 (17.3) 
1,956 (16.2) 
2,345 (19.5) 
1,303 (10.8) 
 
0.829 
 
0 (0.0) 
5 (0.03) 
14 (0.08) 
143 (0.79) 
368 (2.0) 
738 (4.1) 
785 (4.3) 
867 (4.8) 
1,772 (9.7) 
2,379 (13.1) 
2,685 (14.8) 
2,791 (15.3) 
3,493 (19.2) 
2,160 (11.9) 
 
0 (0.0) 
4 (0.04) 
10 (0.1) 
93 (1.0) 
232 (2.5) 
452 (5.0) 
466 (5.1) 
472 (5.2) 
918 (10.1) 
1,176 (12.9) 
1,282 (14.1) 
1,318 (14.5) 
1,643 (18.1) 
1,034 (11.4) 
 
0 (0.0) 
1 (0.01) 
4 (0.04) 
50 (0.5) 
136 (1.5) 
286 (3.1) 
319 (3.5) 
395 (4.3) 
854 (9.4) 
1,203 (13.2) 
1,403 (15.4) 
1,473 (16.2) 
1,850 (20.3) 
1,126 (12.4) 
 
0.180 
Primary ASA grade  
1 
2 
 
3 or above 
 
8,418 (16.2) 
35,533 
(68.4) 
8,015 (15.4) 
 
6,262 (15.7) 
27,709 
(69.4) 
5,939 (14.9) 
 
2,156 (17.9) 
7,824  
(64.9) 
2,076 (17.2) 
 
0.097 
 
2,602 (14.3) 
11,783 
(64.7) 
3,815 (21.0) 
 
1,203 (13.2) 
5,760  
(63.3) 
2,137 (23.5) 
 
1,399 (15.4) 
6,023  
(66.2) 
1,678 (18.4) 
 
0.129 
VTE – chemical 
LMWH (+/-other) 
 
Aspirin only 
Other 
None 
 
36,809 
(70.8) 
3,858 (7.4) 
6,906 (13.3) 
4,393 (8.5) 
 
28,492 
(71.4) 
3,498 (8.8) 
4,119 (10.3) 
3,801 (9.5) 
 
8,317  
(69.0) 
360 (3.0) 
2,787 (23.1) 
592 (4.9) 
 
0.441 
 
 
12,404 
(68.2) 
604 (3.3) 
3,918 (21.5) 
1,274 (7.0) 
 
6,023  
(66.2) 
316 (3.5) 
2,017 (22.2) 
744 (8.2) 
 
6,381  
(70.1) 
288 (3.2) 
1,901 (20.9) 
530 (5.8) 
 
0.106 
VTE – mechanical 
Any vs. none 
 
47,960 
(92.3) 
 
36,805 
(92.2) 
 
11,155 
(92.5) 
 
0.012 
 
17,079 
(93.8) 
 
8,513  
(93.6) 
 
8,566  
(94.1) 
 
0.024 
Surgeon grade 
Consultant vs. other 
 
40,040 
(77.1) 
 
29,565 
(74.1) 
 
10,475 
(86.9) 
 
0.327 
 
15,389 
(84.6) 
 
7,730  
(84.9) 
 
7,659  
(84.2) 
 
0.022 
Surgical approach 
Posterior vs. other 
 
35,035 
(67.4) 
 
26,849 
(67.3) 
 
8,186 
(67.9) 
 
0.013 
 
12,163 
(66.8) 
 
6,028  
(66.2) 
 
6,135  
(67.4) 
 
0.025 
Stem fixation 
Cemented 
 
Uncemented 
 
35,868       
(69.0) 
16,098 
(31.0) 
 
29,908 
(74.9) 
10,002       
(25.1) 
 
5,960  
(49.4) 
6,096  
(50.6) 
 
0.545 
 
10,707 
(58.8) 
7,493  
(41.2) 
 
5,344  
(58.7) 
3,756  
(41.3) 
 
5,363  
(58.9) 
3,737  
(41.1) 
 
0.004 
Table 1
Femoral head size 
(mm) 
Mean (SD) 
 
 
 32.1 (3.3) 
 
 
31.6 (3.2) 
 
 
34.1 (3.0) 
 
 
0.818 
 
 
33.6 (2.8) 
 
 
33.6 (2.8) 
 
 
33.5 (2.8) 
 
 
0.026 
Bearing surface 
MoP  
 
CoP 
 
CoC 
 
34,638 
(66.7) 
12,221 
(23.5) 
5,107  
(9.8) 
 
29,406 
(73.7) 
9,028  
(22.6) 
1,476  
(3.7) 
 
5,232  
(43.4) 
3,193  
(26.5) 
3,631  
(30.1) 
 
0.820 
 
10,128 
(55.7) 
5,306  
(29.2) 
2,766  
(15.2) 
 
5,160  
(56.7) 
2,567  
(28.2) 
1,373  
(15.1) 
 
4,968  
(54.6) 
2,739  
(30.1) 
1,393  
(15.3) 
 
0.045 
Bone graft 
(femoral) 
 
200 (0.4) 
 
123 (0.3) 
 
77 (0.6) 
 
0.048 
 
104 (0.6) 
 
57 (0.6) 
 
47 (0.5) 
 
0.015 
Bone graft 
(acetabular) 
 
2,834 (5.5) 
 
2,068 (5.2)  
 
766 (6.4) 
 
0.050 
 
1,214 (6.7) 
 
631 (6.9) 
 
583 (6.4) 
 
0.021 
 
ASA = American Society of Anesthesiologists; BMI = body mass index; CoC = ceramic-on-ceramic; 
CoP = ceramic-on-polyethylene; LMWH = low molecular weight heparin; MoP = metal-on-
polyethylene; OA = osteoarthritis; SD = standard deviation; SMD = standardised mean difference; 
THA = total hip arthroplasty; TM = trabecular metal; VTE = venous thromboembolism. 
Values in brackets are percentages unless otherwise indicated.  
* Missing data for stated number of hips: BMI (n=21,310). 
Standardised mean differences of 10% or more (>0.100) have been highlighted in bold text 
 
 
 
 
Table 2 Outcomes following primary total hip arthroplasty using trabecular metal and non- 
trabecular metal coated acetabular components in the matched cohort 
Matched cohort Number 
of hips 
(%) 
 
5-year all-cause 
cup revision  
(95% CI) 
 
5-year aseptic cup 
loosening revision 
(95% CI) 
5-year revision 
for infection 
(95% CI) 
Overall 18,200 
(100) 
 
98.6%  
(98.4%-98.8%) 
99.8%  
(99.8%-99.9%) 
99.3%  
(99.1%-99.4%) 
TM cup 9,100 
(50) 
 
99.0%  
(98.7%-99.2%) 
99.9%  
(99.8%-99.9%) 
99.5%  
(99.3%-99.7%) 
Non-TM cup 9,100 
(50) 
 
98.2%  
(97.8%-98.5%) 
99.8%  
(99.6%-99.9%) 
99.1%  
(98.8%-99.3%) 
Univariable SHR 
(95% CI)  
 
 0.57 
(0.43-0.76) 
p < 0.001 
 
0.35  
(0.14-0.90) 
p = 0.029 
0.51 
(0.34-0.76) 
p = 0.001 
Adjusted SHR *  
(95% CI)  
 0.53 
(0.40-0.70) 
p < 0.001 
 
0.29 
(0.12-0.71) 
p = 0.007 
0.46 
(0.31-0.69) 
p < 0.001 
 
CI = confidence interval; SHR = sub-hazard ratio; TM = trabecular metal 
Sub-hazard ratios below 1 represent a reduced risk of the specified outcome in TM cups. 
* Regression models were adjusted for four covariates with residual imbalance following 
matching (age, year of primary surgery, ASA grade, and chemical venous thromboembolism 
prophylaxis). 
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